Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2

Jakob Busch-Petersen; Donald C. Carpenter; Miriam Burman; James Foley; Gerald E. Hunsberger; David J. Kilian; Michael Salmon; Ruth J. Mayer; John G. Yonchuk; Ruth Tal-Singer

doi:10.1124/jpet.117.240705

Research ArticleDrug Discovery and Translational Medicine

Open Access

Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2

Jakob Busch-Petersen, Donald C. Carpenter, Miriam Burman, James Foley, Gerald E. Hunsberger, David J. Kilian, Michael Salmon, Ruth J. Mayer, John G. Yonchuk and Ruth Tal-Singer

Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 338-346; DOI: https://doi.org/10.1124/jpet.117.240705

Jakob Busch-Petersen

GSK R&D, King of Prussia PA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Donald C. Carpenter

GSK R&D, King of Prussia PA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Miriam Burman

GSK R&D, King of Prussia PA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

James Foley

GSK R&D, King of Prussia PA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gerald E. Hunsberger

GSK R&D, King of Prussia PA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

David J. Kilian

GSK R&D, King of Prussia PA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael Salmon

GSK R&D, King of Prussia PA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ruth J. Mayer

GSK R&D, King of Prussia PA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

John G. Yonchuk

GSK R&D, King of Prussia PA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ruth Tal-Singer

GSK R&D, King of Prussia PA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
eLetters
PDF

Submit a Response to This Article

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics

Vol. 362, Issue 2

1 Aug 2017

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Editorial Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2

Message Subject (Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics

Message Body (Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Research ArticleDrug Discovery and Translational Medicine

Danirixin: A Reversible and Selective Antagonist of CXCR2

Jakob Busch-Petersen, Donald C. Carpenter, Miriam Burman, James Foley, Gerald E. Hunsberger, David J. Kilian, Michael Salmon, Ruth J. Mayer, John G. Yonchuk and Ruth Tal-Singer

Journal of Pharmacology and Experimental Therapeutics August 1, 2017, 362 (2) 338-346; DOI: https://doi.org/10.1124/jpet.117.240705

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Research ArticleDrug Discovery and Translational Medicine

Danirixin: A Reversible and Selective Antagonist of CXCR2

Jakob Busch-Petersen, Donald C. Carpenter, Miriam Burman, James Foley, Gerald E. Hunsberger, David J. Kilian, Michael Salmon, Ruth J. Mayer, John G. Yonchuk and Ruth Tal-Singer

Journal of Pharmacology and Experimental Therapeutics August 1, 2017, 362 (2) 338-346; DOI: https://doi.org/10.1124/jpet.117.240705

Share This Article: